News | September 22, 2010

Core Curriculum Published for Structural Heart Disease Treatment

September 23, 2010 – The first consensus document for treating structural heart disease has been published by the Society for Cardiovascular Angiography and Interventions (SCAI). The core curriculum and the results of a survey of physicians and training doctors were published Tuesday in Catheterization and Cardiovascular Interventions and JACC Cardiovascular Interventions.

The curriculum, which was endorsed by the American College of Cardiology Foundation and written by interventional specialists from multiple regions, defines training and credentialing requirements along with program standards for practitioners.

Interventional treatments have evolved rapidly during the past decade, and therapies are helping more patients who previously had to undergo open-heart surgery, or who could not be treated at all. With such rapid advancement, SCAI identified a need for uniformity across training programs and specific credentials and standards for practitioners. Currently, a lack of comprehensive training programs prohibits many practitioners from treating structural heart disease, according to the SCAI survey of 107 U.S.-based interventional cardiologists.

"The primary goal of the core curriculum is to provide patients with the highest level of care and treatment available," said Carlos Ruiz, M.D., Ph.D., FSCAI, professor of pediatrics and medicine and director of the division of congenital and structural heart disease at Lenox Hill Heart and Vascular Institute of New York, and lead author of the core curriculum. "The core curriculum will serve training centers and practitioners dedicated to growing their knowledge and skill base for structural heart disease interventions and provide a forum to discuss the latest treatment advancements for structural heart disease to advance and improve patient care."

The curriculum outlines specific training recommendations and skill requirements, including:

• Superb basic catheterization skills with the ability to achieve unusual types of vascular access and manipulate various catheters, balloons and other devices.

• The ability to competently handle potential complications.

• A knowledge base and interventional skills for a variety of complex structural heart diseases, including appropriate device selection, imaging needs, stenting techniques, managing complications and acute and long-term post-procedural care.

"As structural heart disease procedures advance and become increasingly common, it is essential that practitioners acquire the right set of skills and knowledge base," said SCAI Past President Ted Feldman, M.D., FSCAI, director of cardiac catheterization at Evanston Northwestern Healthcare in Evanston, Ill., and chair of the Structural Heart Disease Council. "Patient care will benefit from those who acquire the skills and training outlined in the core curriculum document."

For more information: www.SCAI.org

Related Content

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive heart valve replacement to open-heart surgery. Photo by Cedars-Sinai. TAVR performs as well as surgery for aortic valve replacement.

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive TAVR heart valve replacement to open-heart surgery. The study showed the two methods have similar outcomes. Photo by Cedars-Sinai.

News | Heart Valve Technology | January 31, 2020
January 31, 2020 — A new study from the Sm...
Abbott Tendyne TMVR, TMVI system received European CE mark clearance in January 2020. The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. Prevents LVOT obstruction.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. The design also eliminated any hardware hanging or folding into the left ventricle, which could cause left ventricular outflow track (LVOT) obstruction, which can prevent blood flow through the aortic valve and to the rest of the body.

Feature | Heart Valve Technology | January 30, 2020
January 30, 2020 — The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received European CE mark
This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial.

This is the latest version of the MitraClip, the G4, which allows each side of the clip to be opened and closed independently to offer more flexibility when capturing the valve leaflets. The device is being used in the REPAIR MR clinical trial. 

News | Heart Valve Technology | January 13, 2020
January 13, 2020 — The U.S.
The Wyss Translational Center in Zurich, Switzerland has developed the LifeMatrix platform to engineer tissues that can be implanted in patients and will grow with them. This technology is being developed for heart valves in younger patients to eliminate the need for repeat surgeries to implant larger prosthetic heart valves as the patient grows.

The Wyss Translational Center in Zurich, Switzerland has developed the LifeMatrix platform to engineer tissues that can be implanted in patients and will grow with them. This technology is being developed for heart valves in younger patients to eliminate the need for repeat surgeries to implant larger prosthetic heart valves as the patient grows.

 

News | Heart Valve Technology | December 26, 2019
While transcatheter heart valve replacement and repair devices are growing in popularity due to their delivery and qu
A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.

A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.

Feature | Heart Valve Technology | November 27, 2019 | Saipriya Iyer
The overwhelming success story for transcatheter aortic valve replacement (TAVR) moving from a science project to bec
A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

A key slide from the TRILUMINATE study one-year results showing the improvement in tricuspid regurgitation from basement with treatment using the transcatheter TriClip device.

News | Heart Valve Technology | November 26, 2019 | Dave Fornell, Editor
November 26, 2019 — The preliminary one-year results of the TRILUMINATE Pivotal Study for Abbott's TriClip device, a
 Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Feature | Heart Valve Technology | October 29, 2019
October 29, 2019 — When Scripps cardiologists discovered early in 2019 that retired National Football League (NFL) gr
Overlay Init